Exhibit 99.2

OraSure Technologies, Inc.

2016 Fourth Quarter and Full-Year

Analyst/Investor Conference Call

February 8, 2017

Prepared Remarks of Douglas A. Michels and Ronald H. Spair

Please see “Important Information” at the conclusion of the following prepared remarks.

Introduction – Doug Michels

Thank you Rena. Good afternoon everyone and welcome to our call.

I am pleased to report that the Company had a terrific fourth quarter. Our financial performance exceeded expectations and we delivered record revenues and earnings for both Q4 and the full year 2016. We also moved forward on all of our strategic initiatives which will be key to continuing our growth in 2017 and beyond. We presented our new strategy at our Analyst Day at the NASDAQ MarketSite in New York City in late November and I am very pleased with the progress we made this past quarter.

Later in today’s call, we will provide an update on each of the key initiatives outlined at our Analyst Day, but before that, we will provide a detailed financial review of the quarter. We will also take your questions.

So with that, let me turn the call over to Ron for his review of our financials.

Fourth Quarter 2016 Financial Results – Ron Spair

Thanks Doug, and good afternoon everyone.

Revenues – Ron Spair

Our fourth quarter 2016 consolidated net revenues increased 10% to $35.5 million, compared to $32.4 million reported in Q4 2015. Our consolidated net product revenues of

$28.6 million approximated those of the prior year period. Higher international sales of our OraQuick^® HIV and HCV products along with higher sales of our molecular collection systems products were largely offset by a decline in domestic sales of our OraQuick^® HIV and HCV products and lower sales of our OraQuick^® Ebola and In-Home HIV tests.

Other Revenues were $6.9 million in the current quarter, of which $6.1 million represents the recognition of exclusivity revenue under the AbbVie HCV co-promotion agreement and $747,000 represents funding we received from BARDA related to our rapid Ebola and Zika products. Other Revenues in the fourth quarter of 2015 included $3.4 million of exclusivity revenue from AbbVie and $319,000 of BARDA funding.

International sales of our HCV test in the fourth quarter of 2016 rose 123% to $2.9 million from $1.3 million in the same period of 2015, primarily due to the first shipments of product to a foreign government as well as the continued expansion of our business in Asia. Domestic OraQuick^® HCV product sales decreased 18% in the fourth quarter of 2016 to $2.2 million from $2.7 million in the prior year period, primarily due to the inclusion in Q4 2015 of a $1.3 million order for a U.S. government HCV testing program which did not repeat in 2016. This was partially offset by an increase in both the number and size of direct orders placed by public health and other customers during the current quarter.

International sales of our HIV products increased 217% to $1.3 million in the fourth quarter of 2016, compared to $415,000 in the fourth quarter of 2015. This increase was due to higher sales in Africa, Asia, the Middle East, and Europe.

Domestic professional HIV sales decreased 26% to $5.1 million in the fourth quarter of 2016, compared to $6.8 million in the fourth quarter of 2015, as result of customer ordering patterns, competition from other products, and budget reductions.

In 2015, we began selling our OraQuick^® Ebola test to the CDC for field testing in Africa. Sales of this product contributed $1.0 million in product revenues during the fourth quarter of 2015. Similar sales in the fourth quarter of 2016 were $197,000. We believe Ebola sales in future periods are likely given ongoing international surveillance efforts.

2

Sales of our OraQuick^® In-Home HIV test decreased 16% to $1.7 million in the fourth quarter of 2016, compared to $2.1 in the fourth quarter of 2015 due to lower retail sales volumes partially offset by higher direct sales into an OTC public health program.

Our molecular collection systems revenues rose 10% to $8.6 million in the fourth quarter of 2016 compared to $7.8 million in the fourth quarter of 2015. Academic sales increased 18% primarily as a result of additional product sales to support a study on autism which commenced in 2016. Sales of our Oragene^® product to commercial customers increased 4%, largely due to product shipped to a new personal genomics customer.

Gross Margin – Ron Spair

Gross margin for the fourth quarter of 2016 was 67% compared to 68% reported for the fourth quarter of 2015. Margin for the current quarter decreased primarily due to an unfavorable product mix and the inclusion in cost of goods sold of severance costs related to our recent corporate restructuring, partially offset by higher AbbVie exclusivity revenues and improved overhead absorption as a result of increased manufacturing activities during the current quarter.

Operating Expenses – Ron Spair

Our consolidated operating expenses for the fourth quarter of 2016 were $16.9 million compared to $17.8 million in the comparable period of 2015. This decrease was the result of lower costs associated with our HCV co-promotion agreement with AbbVie, lower commissions, a reduction in bad debt expense, and a decrease in research and development expenses due to a $1.4 million dispute settlement received from a supplier of raw materials. These decreases were partially offset by severance costs associated with our corporate restructuring, higher legal expenses and an increase in staffing-related costs.

3

Net Income – Ron Spair

From a bottom line perspective, we reported net income of $7.2 million, or $0.13 per share on a fully diluted basis, for the fourth quarter of 2016, compared to net income of $4.6 million, or $0.08 per share, for the same period of 2015.

Cash Flow from Operations and Liquidity – Ron Spair

Turning briefly to our balance sheet and cash flow, we continue to maintain a solid cash and liquidity position. Our cash and short-term investment balance at December 31, 2016 was $120.9 million compared to $101.3 million at December 31, 2015. Cash generated by operating activities through the full year of 2016 was $22.8 million compared to $15.8 million in the same period of 2015.

First Quarter 2017 Consolidated Financial Guidance – Ron Spair

Turning to guidance for the first quarter of 2017, we are projecting consolidated net revenues of approximately $31.0 million to $31.5 million. As you consider this, I think some context regarding the revenue growth inherent in this projection would be useful. When you look back at Q1 2016, we recorded total revenues of $29.1 million which included $3.4 million of exclusivity amortization. The remaining $25.7 million in this figure represents product revenues and BARDA funding. With the AbbVie revenues ending in 2016, our Q1 2017 guidance of $31.0 million – $31.5 million consists entirely of product and BARDA revenues and represents growth of 21% to 23% from the comparable revenues in Q1 2016.

We are also projecting consolidated net income of approximately $0.17 to $0.18 per share for Q1 of 2017. This guidance reflects the absence of both revenues and costs associated with the AbbVie HCV co-promotion agreement as well as a lower gross margin contribution expected from increasing international revenues during the period. This net income guidance also includes the after-tax impact of the Ancestry settlement announced earlier this week.

And with that, I will now turn the call back over to Doug.

4

Business Update – Doug Michels

Thanks, Ron. During our Analyst Day, we described the focus of our long-term strategy as growing our business in two key areas, which we refer to as growth pillars. The first pillar is our infectious disease business which includes our HCV, HIV self-test, Ebola, Zika and TB programs. The second pillar is our molecular business which consists of our personal genomics and microbiome products.

Infectious Disease Testing – Doug Michels

Let me first comment on the infectious disease business.

HCV Elimination Programs

The strong growth we are realizing and expect in our international HCV business is attributable to country-wide or large-scale HCV elimination or testing programs. Last year, we entered into a supply contract with a foreign government for $18 million of both HCV and HIV products. The majority of this contract is for our OraQuick^® HCV test to support a nation-wide HCV testing and treatment program. Initial shipments occurred in Q4 and will continue throughout 2017. This is the largest product supply contract in OraSure’s history and we believe it is just the beginning for these types of opportunities.

At the Analyst Day, we indicated we are working with other countries that are initiating large scale HCV testing programs. As a result of these efforts, we recently received a large order for both HCV and HIV tests from one of those countries. Some initial smaller purchases were also made by another country, which is typical as a precursor to initiating a larger scale HCV testing program. The list of countries evaluating broad testing programs is growing and we believe that additional significant opportunities will emerge over time.

While our international HCV business has stolen the spotlight lately, we are equally optimistic about growth opportunities in the domestic market. We expect continued growth in HCV sales in the U.S., primarily due to increasing demand in the public health market and from government accounts, in addition to drug treatment and community health centers.

5

HIV Self Testing

A second growth driver for infectious disease is HIV self-testing. We have previously discussed our ongoing work with Population Services International, or PSI, in support of a pilot program known as the “Self Testing in Africa” or “STAR” project. This pilot is being funded by UNITAID and is designed to deploy approximately 750,000 OraQuick^® HIV self-tests in Sub-Saharan Africa during the first phase. Continued sales under this program are expected in 2017. We recently received an additional order from PSI for approximately 350,000 tests, which we are preparing for shipment here in the first quarter.

Our HIV self-tests are now being successfully deployed in Malawi, Zambia and Zimbabwe. Field reports on the use of our tests continue to be positive and we believe our product is fully meeting the needs of the STAR project. We are also working with several countries outside of STAR that have initiated studies as a precursor to implementing community based HIV self-testing programs.

To ensure the long-term success and stability of our international HIV self-testing business, we are pursuing the prequalification of our product by the WHO. Our submission is under active review and we expect to receive feedback later this month. WHO prequalification will enable countries purchasing our test to access global funding sources such as the Global Fund, UNITAID and PEPFAR.

Emerging Diseases

Another infection disease growth driver is in the area of emerging diseases, where our two focus programs are Ebola and Zika.

Our OraQuick^® Ebola test is being used in several West African countries as a part of ongoing surveillance efforts. We shipped a small quantity of product in Q4 and an

6

additional small order here in the first quarter. We have additional orders planned for later in 2017. Our product remains the only rapid Ebola test with indications of use for both live patients and cadavers. Our clinical work for this product remains on track for a 510(k) submission to the FDA in late 2017 or early 2018. Given the history of the Ebola epidemic, the sporadic cluster outbreaks in 2016 and the ongoing transportation and infrastructure improvements in Africa that facilitated the last outbreak, we believe it is unlikely that we have seen the last of Ebola. We expect our product will be an important global health tool in the future.

With respect to Zika, our efforts to optimize our test are progressing. We remain on track to submit for Emergency Use Authorization, or EUA, from the FDA as early as Q2 of this year. We are committed to expediting the required optimization and clinical work wherever possible. Active Zika virus transmission continues in Central and South America, with sporadic cases of travel-related transmission still being reported in Florida. We anticipate that outbreaks similar to those experienced in the U.S. in 2016, particularly in Florida, Texas, Hawaii, California and other states and territories, will likely occur in 2017.

Tuberculosis

A final growth driver for the infectious disease business is our tuberculosis product. The clinical studies being performed by the Foundation for Innovative New Diagnostics, or FIND, in support of WHO endorsement of our OMNIgene^®•Sputum product were completed in December. FIND has indicated they expect to issue a final data dossier to the WHO by the end of February. The WHO has indicated that it will review the FIND data and issue a broader review of all commercial sputum transport reagents later this year. As you know, WHO endorsement is critical to enable future customers to access global funding sources for product purchase.

We also continue to make progress on commercializing this product while pursuing WHO endorsement. DNA Genotek is negotiating with two foreign Ministries of Health in countries with high TB prevalence for the deployment of our OMNIgene^®•Sputum on a national scale.

7

In addition, a major and successful evaluation funded by USAID was completed in late 2016 and the results were presented to another Health Ministry, USAID and several surrounding countries to inform national testing laboratories on the routine use of OMNIgene^®•Sputum. Discussions with these countries and USAID are continuing.

Finally, a National Tuberculosis and Leprosy Control Program in Africa has begun planning a nation-wide pilot of OMNIgene^®•Sputum as a follow-up to a prior laboratory assessment which singled out sputum transport as a major area for improvement. As you can see, there is a lot of activity occurring with respect to tuberculosis and we remain very optimistic about the prospects for this part of our business.

Molecular Business Growth Drivers – Doug Michels

Turning to our molecular growth pillar, there are two primary drivers – our genomics business and the microbiome market.

Genomics

During the fourth quarter, there were several developments in our genomics business, some of which we previewed at the Analyst Day.

8

Microbiome

Our microbiome business also continues to develop nicely. The number of microbiome kits sold in Q4 increased by 47% over Q3 and 91% over Q4 of 2015. We expect our microbiome business to double in 2017 from the roughly $1.1 million in revenues recorded in 2016.

The majority of our revenues have been derived from our gut or stool sample collection kits and related services with a smaller percentage derived from kits for other sample types. Academic customers continue to provide the vast majority of our microbiome sales, although the proportion of sales to commercial customers is growing. We are acquiring new commercial customers across several market segments, including direct-to-consumer firms, clinical stage biotechs and pharmaceutical companies that utilize both

9

our kits and the related order fulfillment, wet lab and analytical services we offer. Academic and clinical research scientists are also demonstrating a continued need for standardization in their case control and longitudinal studies with both segments generating repeat business for both kits and our microbiome services.

Operations Update – Doug Michels

A final area I want to discuss is the significant work in our Operations Department to meet the increasing demand for our diagnostic products.

As discussed on the last call, our second automated production line for the assembly of OraQuick^® products has been delivered and installed and is now being validated. This equipment will supplement our current automated and manual production lines. The second line will be capable of producing all OraQuick^® platform products and will initially manufacture our HIV and HCV products. When fully operational in mid-2017, the equipment will be able to produce approximately 8.0 million additional devices per year.

Because of the substantial growth projected in international markets where pricing is sometimes lower, we have initiated an effort to evaluate our global manufacturing. We have hired a very capable, well-known consulting firm to help us optimize the global footprint for the manufacture of our products that will align with our projections in international markets, minimize our cost of goods and logistics expenses, and maintain the highest levels of product quality and customer service. This effort is well under way and we expect completion sometime in the middle of this year. After potential strategies are identified and evaluated, we will make final decisions and begin implementation.

Conclusion

So, in summary, it was a highly productive end to 2016. We delivered a strong financial performance in the fourth quarter and advanced our key strategic objectives. Our international HIV and HCV products and our molecular collection systems business continue to fuel strong growth for OraSure. We believe the recent trends in these businesses will continue and will provide for solid growth in 2017.

10

If you missed our Analyst Day, I would like to emphasize the key take away from that day – that OraSure is in the very early stages of multiple large market opportunities. Through product innovation and the development of additional ways for customers to use our products, the door has opened to several new and large market opportunities that did not exist for us even a few years ago. We are very excited about OraSure’s prospects and we believe we are well positioned to capitalize on those opportunities. These are definitely exciting times for the Company.

And with that, I will now open the floor to your questions. Operator, please proceed.

* * * *

[Q&A session]

Final Conclusion – Doug Michels

Thank you for participating on today’s call and for your continued interest in OraSure. Have a good afternoon and evening.

Important Information

This document contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products;

11

ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; impact of replacing distributors; inventory levels at distributors and other customers; ability of the Company to achieve its financial and strategic objectives and continue to increase its revenues; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment levels and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (“CDC”) and other agencies; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to meet financial covenants in credit agreements; ability to attract and retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and

12

regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2015, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this call, and we undertake no duty to update these statements.

13